Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

There are tons and tons of scary movies about vampires, demons and ghosts—but werewolf movies tend to only come around once in a blue moon (in other words, far less frequently than the full moons that ...

On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL), a micro-cap biotech company valued at just $31.07 million, in three separate transactions, with the total value ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) common stock over three days, with the transactions totaling approximately $61,787. The sales occurred between ...